Peanut flour

DRUG5 trials

Sponsors

University of Texas Southwestern Medical Center, University of North Carolina, Chapel Hill, Massachusetts General Hospital, Johns Hopkins University

Conditions

Peanut AllergyTreatment Efficacy

Phase 1

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

TerminatedNCT01274429

University of North Carolina, Chapel HillPeanut Allergy

Start: 2010-12-31End: 2015-11-30Updated: 2018-03-27

Tolerance Following Peanut Oral Immunotherapy

CompletedNCT01750879

Massachusetts General HospitalPeanut Allergy

Start: 2013-08-31End: 2017-07-11Updated: 2021-07-28

Phase 2

Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

CompletedNCT03345160

Johns Hopkins UniversityTreatment Efficacy

Start: 2018-04-27End: 2020-10-07Updated: 2021-10-29

Unknown Phase

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

CompletedNCT01074840

University of Texas Southwestern Medical CenterPeanut Allergy

Start: 2010-02-28End: 2014-08-31Updated: 2014-12-03

High Threshold Peanut Challenge Study

CompletedNCT02698033

Massachusetts General HospitalPeanut Allergy

Start: 2015-12-09End: 2019-08-22Updated: 2019-10-03

Related Papers

Epitope-Specific IgE Profiles are Predictive of Desensitization and Remission in the IMPACT Trial.

2026-07-24

Genetic Determinants of Peanut‐Specific <scp>IgG4</scp> Levels in the Context of Sustained Oral Peanut Exposure in the <scp>LEAP</scp> Study

Immunology2026-01-30

Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.

2022-01-01208 citations